25, Jun, 2022
Glenmark Pharma shares gain on DCGI nod for Phase 1 trial of novel molecule

Glenmark

Shares of Glenmark Pharma were trading 1 per cent higher at Rs 487.15 after the company announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel smallmolecule, GRC 54276, […]